Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells. Zikry TM, Wolff SC, Ranek JS, Davis HM, et al. Proc Natl Acad Sci U S A 2024;121:e2309261121.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Zikry TM, Wolff SC, Ranek JS, Davis HM, et al. Cell cycle plasticity underlies fractional resistance to palbociclib in ER+/HER2- breast tumor cells. Proc Natl Acad Sci U S A 2024;121:e2309261121.
PMID: 38324568